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a  b  s  t  r  a  c  t
Objectives:  The  clinical  beneﬁt  of  ezetimibe,  an intestinal  cholesterol  transporter  inhibitor,  for  treatment
of  postprandial  hyperlipidemia  was  assessed  in  subjects  who  ingested  a high-fat  and high-glucose  test
meal to  mimic  westernized  diet.
Methods:  We  enrolled  20  male  volunteers  who  had  at least  one  of  the  following:  waist  circumference
≥  85  cm,  body  mass  index  ≥  25 kg/m2, or triglycerides  (TG)  from  150  to 400  mg/dL.  After  4 weeks  of
treatment  with  ezetimibe  (10 mg/day),  the  subjects  ingested  a high-fat  and high-glucose  meal.  Then
changes  in serum  lipid and  glucose  levels  were  monitored  after  0,  2, 4, and  6 h, and  the  area  under  the
curve  (AUC)  was  calculated  for  the  change  in  each  parameter.
Results  and  conclusion:  At 4  and  6 h  postprandially,  TG  levels  were  decreased  (p  < 0.01)  after  4 weeks  of
ezetimibe  treatment,  and  the  AUC  for TG  was  also  decreased  (p  < 0.01). Apolipoprotein  B48  (apo-B48)zetimibe levels  at  4 and  6 h postprandially  were  signiﬁcantly  decreased  after ezetimibe  treatment  (p <  0.01  and
p  < 0.001,  respectively),  and  the  AUC  for apo-B48  was  also  signiﬁcantly  decreased  (p  < 0.01).  Blood  glucose
and  insulin  levels  at 2 h  postprandially  were  signiﬁcantly  decreased  by ezetimibe  (p < 0.05).  The  AUCs  for
blood  glucose  and  insulin  were  also signiﬁcantly  decreased  (p  < 0.05  and  p < 0.01,  respectively).  Since
ezetimibe  improved  postprandial  lipid and  glucose  metabolism,  this  drug  is  likely  to  be  beneﬁcial  for
dyslipidemia  in patients  with  postprandial  metabolic  abnormalities.
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Fat intake of the Japanese population has been increasing
harply because of westernization of their diet since the 1970s. Con-
equently, the prevalence of dyslipidemia in Japan has increased
pproximately 8-fold [1,2]. The increased fat intake results in
nhancement of chylomicron secretion and causes postprandial
etabolic abnormalities. Postprandial hyperlipidemia is charac-
erized by pronounced and prolonged hypertriglyceridemia. It is
ommonly seen in obese individuals, patients with metabolic syn-
rome, and patients with abnormalities of glucose metabolism,
ncluding those with glucose intolerance. Postprandial hyperlipi-
emia results from an increase in remnant lipoproteins and small
ense low-density lipoprotein (LDL) that are highly atherogenic
nd closely linked to insulin resistance, fatty liver, and vascu-
ar endothelial dysfunction [3,4]. Postprandial hyperlipidemia has
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been also shown to be a risk factor that is independent of the choles-
terol level [5,6].
To achieve improvement in postprandial hyperlipidemia, diet
and exercise therapy for lifestyle modiﬁcation is most important.
However, patients usually fail to complete diet and exercise regi-
mens because of temptation to overeat, irregular mealtimes, and
limits on performing exercise due to insufﬁcient time and fatigue.
This represents an “unmet medical need” for the modern Japanese
population and effective pharmacotherapy should therefore be
established for persons with insufﬁcient improvement of their
lifestyle.
In recent years, the cholesterol transporter protein
Niemann–Pick C1-like 1 (NPC1L1), which is expressed by small
intestinal epithelial cells, has been cloned, and its function has been
elucidated [7].  Ezetimibe selectively inhibits cholesterol absorp-
tion by binding to NPC1L1, and this drug has become available in
Japan for clinical use. Ezetimibe decreases LDL cholesterol (LDL-C)
levels by about 20% and also improves both hypertriglyceridemia
and low high-density lipoprotein cholesterol (HDL-C) levels [8].
The Fujita Ezetimibe Study Assembly (FESTA) previously revealed
that ezetimibe treatment improves hyperinsulinemia as well as
vier Ltd. All rights reserved.


























































Proﬁle of the subjects.
Number of subjects 20
Age 40.5 ± 5.1 years
Height 171.7 ± 5.5 cm
Weight 74.4 ± 7.6 kg
Body mass index 25.6 ± 2.9 kg/m2
Waist circumference 87.2 ± 6.0 cm
Triglycerides 186.0 ± 89.8 mg/dL
HDL-cholesterol 53.5 ± 11.0 mg/dL
LDL-cholesterol 141.3 ± 29.0 mg/dL
Fasting blood glucose 100.7 ± 12.1 mg/dL96 S. Hiramitsu et al. / Journal 
diponectin level [9].  However, the mechanism by which ezetim-
be modiﬁes glucose and lipid metabolism is not well understood.
zetimibe has been documented to prevent lipid-related increase
f chylomicrons and to improve insulin resistance and hepatic lipid
ccumulation in a rat model of metabolic syndrome [10]. Ezetimibe
as also been known to prevent the increase in triglycerides (TG),
emnant lipoproteins, and fatty acids after a lipid load in patients
ith mixed dyslipidemia. Therefore, improvement in postprandial
ipid metabolism by ezetimibe is thought to account for its effects
n glucose and fat metabolism [11]. That is, ezetimibe is suggested
o not only improve circulating lipid levels, but also modify glu-
ose and fat metabolism by alleviating various postprandial lipid
bnormalities.
In previous studies [11], however, the inﬂuence of ezetimibe on
ostprandial metabolic abnormalities was assessed after loading
ith fat alone, although fats are ingested together with carbohy-
rates in ordinary meals. It is therefore necessary to investigate the
fﬁcacy of ezetimibe in a more normal dietary environment.
Accordingly, we investigated the effects of ezetimibe on post-
randial lipid and glucose metabolism by giving a simultaneous
at and glucose load to obese individuals, who commonly have
ostprandial metabolic abnormalities, and patients with hyper-
riglyceridemia.
ethods
Japanese men  aged 20–65 years who had not received lipid-
owering agents or oral antidiabetic agents for at least 12 weeks
ere eligible for participation in this study if they had at least one
f the following: (1) a waist circumference ≥85 cm;  (2) a body mass
ndex (BMI) ≥25 kg/m2; and (3) a TG level from 150 to 400 mg/dL.
ersons with a history of hypersensitivity to ezetimibe and patients
ith serious hepatic disease, renal disease, or atherosclerosis were
xcluded from the study, as were individuals who were judged by
he investigator to be inappropriate for the study for other rea-
ons. Before entering the study, all subjects gave written informed
onsent to participation.
After fasting for at least 12 h, subjects were given a high-fat and
igh-glucose meal for breakfast on Day 1. Then they received oral
zetimibe (10 mg/day) once daily for 4 weeks. After completing
zetimibe treatment, the subjects again ate a high-fat and high-
lucose meal for breakfast. A fast-food meal (a hamburger with
ausage and egg, apple pie, and Coca-Cola®, which are widely avail-
ble and have stable major ingredients) was chosen as the high-fat
nd high-glucose test meal (1001 kcal; protein, 31.6 g; lipids, 61.4 g;
arbohydrate, 79.8 g; cholesterol, 299 mg). Subjects were requested
o eat the test meal in 20–30 min.
At 0, 2, 4, and 6 h after the test meal, blood was sampled to eval-
ate the changes in serum lipid levels and glucose metabolism. The
erum lipids measured were TG, HDL-C, LDL-C, apolipoprotein B,
nd apolipoprotein B48, which is speciﬁcally contained in dietary
ipoprotein. LDL-C levels were determined by direct measurement
nd not by calculation, since the postprandial TG level was  pre-
icted to exceed 400 mg/dL. Blood glucose and insulin levels were
easured for the assessment of glucose metabolism. Measurement
f parameters was performed by a contract laboratory (SRL).
Changes in lipid and glucose parameters after ingestion of the
est meal and the area under the concentration vs. time curve (AUC)
f each parameter were compared before and after treatment with
zetimibe to evaluate its effects on lipid and glucose metabolism.
To assess changes in each laboratory parameter after the test
eal, the Z test was initially performed to conﬁrm a normal dis-
ribution. The Bonferroni multiple comparison test was performed
f a normal distribution was conﬁrmed, while Dunnet’s test was
mployed if the distribution was not normal. The postprandialFasting insulin 10.2 ± 5.2 IU/mL
change in each laboratory parameter and the AUC of the change
were compared between baseline and after ezetimibe treatment
using the paired t-test, with signiﬁcance being accepted at p < 0.05.
The present study was conducted after being approved by the
Ethics Committee of Fujita Health University School of Medicine
and under the supervision of this committee.
Results
Informed consent was  obtained from 20 volunteers with a mean
age of 40.5 ± 5.1 years, BMI  of 25.6 ± 2.9 kg/m2, and fasting TG level
of 186.0 ± 89.8 mg/dL (Table 1).
Fasting lipid and glucose metabolism
Baseline fasting TG level was  186.0 ± 89.8 mg/dL and decreased
to 140.3 ± 55.2 mg/dL after 4 weeks of treatment with ezetimibe
(p < 0.01) (Table 2); meanwhile, HDL-C level was unchanged from
baseline after treatment. LDL-C decreased from 141.3 ± 29.0 mg/dL
at baseline to 112.1 ± 22.6 mg/dL after ezetimibe treatment
(p = 0.001), with the percent change being −19.2 ± 15.3%.
Apolipoprotein B decreased from 118.0 ± 23.9 mg/dL at base-
line to 94.5 ± 19.7 mg/dL after ezetimibe treatment (p < 0.01),
with the percent change being −19.1 ± 11.7%. The apolipopro-
tein B48 level was  6.5 ± 4.5 g/mL at baseline and it declined to
4.6 ± 2.4 g/mL after treatment (p < 0.05). The fasting glucose level
decreased from 100.7 ± 12.1 mg/dL at baseline to 97.7 ± 10.6 mg/dL
after treatment (p < 0.01), but the fasting insulin level showed no
signiﬁcant change after ezetimibe treatment.
Changes in lipid and glucose metabolism after the test meal
The baseline TG level was 186.0 ± 89.8 mg/dL before the high-
fat and high-glucose meal, and it gradually increased after
ingestion of the meal to 257.3 ± 102.5 mg/dL (p < 0.001) at 2 h,
417.1 ± 174.4 mg/dL (p < 0.001) at 4 h, and 415.7 ± 231.2 mg/dL
(p < 0.001) at 6 h postprandially. HDL-C and LDL-C decreased
slightly after ingestion of the meal (Fig. 1). The apolipoprotein
B level showed no signiﬁcant change after ingestion of the meal
(Fig. 2). The baseline apolipoprotein B48 level was  6.5 ± 4.5 g/dL,
and it gradually increased to 12.5 ± 5.3 g/mL (p < 0.001) at 2 h,
15.3 ± 6.2 g/mL (p < 0.001) at 4 h, and 14.6 ± 6.5 g/mL (p < 0.001)
at 6 h postprandially (Fig. 2). The baseline blood glucose level
showed a signiﬁcant decrease at 2 and 4 h postprandially (Fig. 1,
both p < 0.05). The blood insulin level was 10.1 ± 5.2 U/mL before
the test meal, while it was 32.8 ± 22.9 U/mL (p < 0.05) at 2 h,
16.9 ± 9.3 U/mL (p < 0.05) at 4 h, and 10.1 ± 5.6 U/mL at 6 h post-
prandially (Fig. 1).
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Fig. 1. Effects of the test meal before (open circles) and after (solid circles) ezetimibe treatment. The subjects (n = 20) received a high-fat and high-glucose meal (1001 kcal,
protein  31.6 g, fat 61.4 g, carbohydrate 79.8 g, cholesterol 299 mg)  before and after the treatment with ezetimibe. Blood samples were obtained while fasting and 2, 4, and
6  h after the test meal. (A) Triglycerides; (B) high-density lipoprotein cholesterol; (C) low-density lipoprotein cholesterol; (D) blood glucose; and (E) insulin. The Bonferroni
t-test  was used to compare before and after the test meal (*p < 0.05; **p < 0.01; ***p < 0.001). The paired t-test was employed to compare before and after treatment with
ezetimibe (#p < 0.05; ##p < 0.01; ###p < 0.001).
Table 2
Parameters of lipid and glucose metabolism before and after ezetimibe treatment.
Before ezetimibe After ezetimibe Percent change p Value
Body weight (kg) 74.4 ± 7.6 74.4 ± 7.7 −0.1 ± 1.3 0.6727
BMI  (kg/m2) 25.6 ± 2.9 25.6 ± 2.9 0.01 ± 1.2 0.9580
Waist  circumference (cm) 87.2 ± 6.0 87.0 ± 6.3 −0.3 ± 1.3 0.3935
Triglycerides (mg/dL) 186.0 ± 89.8 140.3 ± 55.2 −16.7 ± 31.0 0.0075
HDL-cholesterol (mg/dL) 53.5 ± 11.0 51.7 ± 10.6 −2.1 ± 11.6 0.2082
LDL-cholesterol (mg/dL) 141.3 ± 29.0 112.1 ± 22.6 −19.2 ± 15.3 0.001
Apolipoprotein B (mg/dL) 118.0 ± 23.9 94.5 ± 19.7 −19.1 ± 11.7 <0.001
Apolipoprotein B48 (g/m) 6.5 ± 4.5 4.6 ± 2.4 −19.7 ± 28.4 0.007a
Fasting blood glucose (mg/dL) 100.7 ± 12.1 97.7 ± 10.6 −2.8 ± 4.4 0.0094
Fasting insulin (IU/mL) 10.2 ± 5.2 9.3 ± 7.4 −9.9 ± 39.1 0.4473
Parameters are shown as the mean ± SD for 20 patients. Statistical analysis was  done with the paired t-test.
a Wilcoxon signed rank test.
Table 3
Area under the curve for parameters of lipid and glucose metabolism before and after ezetimibe treatment.
Before ezetimibe After ezetimibe Percent change p Value
Triglycerides 1950.3 ± 843.1 1522.6 ± 486.6 −13.8 ± 30.4 0.009
LDL-cholesterol 811.0 ± 168.0 654.3 ± 133.4 −17.8 ± 16.0 p < 0.001
HDL-cholesterol 303.9 ± 62.7 300.7 ± 52.8 0.0 ± 10.6 0.635
Apolipoprotein B 695.3 ± 139.0 566.2 ± 112.8 −17.6 ± 11.8 p < 0.001
Apolipoprotein B48 76.7 ± 31.9 59.9 ± 19.2 −17.2 ± 21.0 p < 0.001a
Blood glucose 556.9 ± 66.6 540.4 ± 82.4 −3.1 ± 5.7 0.043
Insulin  119.7 ± 61.3 97.7 ± 53.9 −16.6 ± 27.7 0.008
Parameters are shown as the mean ± SD for 20 patients. Statistical analysis was  done by the paired t-test.
a Wilcoxon signed rank test.
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Fig. 2. Fat and glucose loading test before (open circles) and after (solid circles) ezetimibe treatment. The subjects (n = 20) received a high-fat and high-glucose meal (1001 kcal,
protein 31.6 g, fat 61.4 g, carbohydrate 79.8 g, cholesterol 299 mg)  before and after the treatment with ezetimibe. Blood samples were obtained while fasting and 2, 4, and 6 h
after  the test meal. (A) Apolipoprotein B and (B) apolipoprotein B48. (C and D) Photos of blood samples from a typical case are shown. The color of the sample changes from
c  with e
w as  do





























(lear  while fasting to white (lipemia) after the fat and glucose load before treatment
hite  (lipemia) to normal after treatment with ezetimibe (D). Statistical analysis w
*p  < 0.01; ***p < 0.001), and was  done with the paired t-test to compare before and
ffect of ezetimibe on lipid and glucose metabolism after the test
eal
The TG level at 4 h after ingestion of the high-fat and high-
lucose meal was 417.1 ± 174.4 mg/dL before treatment and it
ecreased to 329.6 ± 107.0 mg/dL (p < 0.01) after 4 weeks of eze-
imibe treatment. The baseline TG level at 6 h postprandially was
15.7 ± 231.2 mg/dL and this decreased to 272.8 ± 131.8 mg/dL
p < 0.01) after ezetimibe treatment (Fig. 1). The AUC for the
ostprandial change in TG decreased from 1950.3 ± 843.1 before
reatment to 1522.6 ± 486.6 after ezetimibe treatment (Table 3,
 < 0.01). LDL-C levels at 2 and 4 h postprandially were signiﬁ-
antly decreased after ezetimibe treatment and were similar to the
reprandial levels (Fig. 1), with LDL-C showing a similar reduc-
ion at each time of measurement. The AUC for the change in
DL-C was also signiﬁcantly decreased by ezetimibe treatment
Table 3, p < 0.001). HDL-C showed no signiﬁcant changes at any
ime of assessment, and no signiﬁcant change in the AUC for HDL-C
as noted either (Fig. 1 and Table 3). The apolipoprotein B level
as signiﬁcantly decreased at 2, 4, and 6 h postprandially, and
he decrease was similar at all times of assessment, as it was for
DL-C. The AUC for the postprandial change of apolipoprotein B
as also signiﬁcantly decreased by ezetimibe treatment (Fig. 2
nd Table 3, p < 0.001). The apolipoprotein B48 level at 4 h post-
randially decreased from 15.3 ± 6.2 g/mL before treatment to
1.8 ± 3.6 g/mL (p < 0.01) after ezetimibe treatment, while the
evel at 6 h decreased from 14.6 ± 6.5 g/mL to 9.7 ± 3.9 g/mL
p < 0.001). The AUC for the postprandial change of apolipopro-
ein B48 showed a signiﬁcant decrease from 76.7 ± 31.9 mg/dL
efore treatment to 59.9 ± 19.2 mg/dL after ezetimibe treatment
Fig. 2 and Table 3, p < 0.001). At 2 h postprandially, blood glucosezetimibe (C). Then the sample obtained after the fat and glucose load changes from
ne with the Bonferroni t-test to compare before and after the test meal (*p < 0.05;
the treatment with ezetimibe (#p < 0.05; ##p < 0.01; ###p < 0.001).
was 92.4 ± 25.9 mg/dL before treatment versus 84.7 ± 31.0 mg/dL
after ezetimibe treatment (Fig. 1, p < 0.05). The AUC for the post-
prandial change of blood glucose showed a signiﬁcant decrease
from 556.9 ± 66.6 before treatment to 540.4 ± 82.4 after treat-
ment (Table 3, p < 0.05). At 2 h postprandially, the blood insulin
level was  32.8 ± 22.9 U/mL before treatment as compared with
25.7 ± 19.1 U/mL after ezetimibe treatment (Fig. 1, p < 0.05). The
AUC for the postprandial change of insulin was signiﬁcantly
decreased from 119.7 ± 61.3 before treatment to 97.7 ± 53.9 after
treatment (Table 3, p < 0.01).
Also the incremental area under the curve (IAUC) for postpran-
dial change of TG, apolipoprotein B48, glucose, and insulin were
signiﬁcantly decreased after ezetimibe treatment (Table 4).
No adverse events or laboratory abnormalities of clinical rele-
vance were observed during the study period.
Discussion
In recent years, the selective cholesterol-absorption inhibitor
ezetimibe has been available for clinical use, allowing the reg-
ulation of cholesterol absorption as an option for the treatment
of hyperlipidemia. Restriction of dietary fat intake is of vital
importance for modern Japanese people, who  have an increased
cholesterol intake because of westernization of their diet. How-
ever, if sufﬁcient efﬁcacy is not obtained by diet alone, cholesterol
absorption inhibitors like ezetimibe may  provide an effective
treatment option. Since this drug undergoes enterohepatic circula-
tion, once-daily administration of ezetimibe achieves considerable
improvement in serum lipid levels [12]. In the Japanese clinical
study, ezetimibe monotherapy achieved an approximately 20%
reduction in serum LDL-C level [8]. Previously, FESTA evaluated
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Table  4
Incremental area under the curve for parameters of lipid and glucose metabolism before and after ezetimibe treatment.
Before ezetimibe After ezetimibe Percent change p Value
Triglycerides 1117.6 ± 454.5 920.3 ± 281.7 −9.7 ± 32.0 0.0280
Apolipoprotein B48 46.7 ± 20.0 38.5 ± 12.8 −8.3 ± 13.5 0.0133

























































aInsulin 43.0 ± 25.2 
riglycerides and apo-48 (0–4 h), blood glucose and insulin (0–2 h).
he effect of ezetimibe (10 mg  once daily) on serum lipids, glucose
etabolism, and lipid metabolism in 120 patients with dyslipi-
emia during treatment for 12 weeks, and demonstrated a decrease
n LDL-C by about 20% along with a decrease in the fasting insulin
evel and an increase in adiponectin [9].  That is, ezetimibe seemed
o not only improve serum lipid levels but also metabolic abnormal-
ties, including those of glucose metabolism and lipid metabolism.
zetimibe is expected to be useful in Japan because patients with
he combination of obesity, metabolic syndrome, and/or glucose
ntolerance [13] have been increasing in number due to progressive
esternization of the diet. In recent years, there have been some
eports about the mechanisms by which ezetimibe may  improve
etabolism. Masuda et al. [11] administered ezetimibe (10 mg  once
aily) for 2 months to patients with type IIb hyperlipidemia and
ave them a lipid load before and after the treatment to evaluate
nﬂuence of ezetimibe on postprandial lipid abnormalities. They
eported that ezetimibe inhibited increase of serum apolipoprotein
48 and also inhibited increase in fatty acids. It was also reported
hat ezetimibe blocks the postprandial increase of chylomicrons
ue to inhibition of chylomicron secretion from the small intestines
14]. These postprandial effects of ezetimibe are thought to have a
avorable impact on glucose and lipid metabolism. However, the
ffects of ezetimibe on postprandial metabolism have only been
nvestigated after a fat load, and no investigation has assessed
he effect of ezetimibe on postprandial glucose metabolism after
 glucose load. People ingest both fat and carbohydrate during nor-
al  meals, so studies simulated with usual diet were required.
herefore, we  investigated the effects of ezetimibe on postprandial
ipid and glucose metabolism in patients with obesity or hyper-
riglyceridemia, who are likely to have postprandial metabolic
bnormalities, after a simultaneous fat and glucose load. A fast-
ood meal was  used as loading so that its nutritional content was
oth known and reproducible. The increase in serum TG at 4 and 6 h
fter ingestion of the test meal was signiﬁcantly inhibited as a result
f ezetimibe treatment, and the increase in apolipoprotein B48 was
imilarly inhibited at 4 and 6 h. In addition, the AUCs for both TG
nd apolipoprotein B48 were signiﬁcantly decreased, suggesting
n improvement in postprandial hyperlipidemia. Since HDL-C and
DL-C levels tended to decrease after a fat load, it was suggested
hat lipoprotein metabolism was delayed. This ﬁnding showed lit-
le change after treatment with ezetimibe. It is therefore suggested
hat ezetimibe treatment resulted in inhibition of chylomicron
roduction rather than acceleration of lipoprotein metabolism. In
act, Nakamura et al. reported that the combination of ezetimibe
nd statin therapy signiﬁcantly reduced remnant lipoproteinemia,
hich correlates chylomicron, compared with doubling of statin
ose therapy [14].
Tremblay et al. [15] investigated the effect of ezetimibe on serum
polipoprotein B48 levels after a fat load in patients with mixed
yslipidemia. Their study showed that metabolism of apolipopro-
ein B48 was little changed while its production was enhanced, and
he results of the present study are consistent with their results. In
ddition, we  found that the blood glucose level at 2 h after the test
eal was signiﬁcantly decreased, resulting in a signiﬁcant reduc-
ion in the AUC for glucose. The serum insulin level also showed
 signiﬁcant reduction at 2 h postprandially (p < 0.05), as did the.0 ± 22.8 −13.6 ± 35.9 0.0176
AUC of insulin (p < 0.01). That is, an increase of glucose was inhib-
ited even though the circulating insulin level was  decreased as
a result of ezetimibe treatment, suggesting that insulin sensitiv-
ity was  improved by ezetimibe. A study in obese rats conducted
by Yoshida et al. [10,16] showed that ezetimibe inhibited expres-
sion of the gene for sterol regulation element binding protein-1c
(SREBP1c), which is a transcription factor involved in hepatic fatty
acid synthesis, and that it improved chylomicrons, serum lipids
(including fatty acids), and insulin resistance. It was  also reported
that ezetimibe decreased small intestinal expression of the gene
for fatty acid transfer protein-4 (FATP-4) and inhibited fatty acid
absorption [17]. The mechanism by which the supposedly selective
cholesterol absorption inhibitor ezetimibe also inhibits fatty acid
absorption is not well understood. However, inhibition of chylomi-
cron formation due to depletion of cholesterol in small intestinal
cells after treatment with ezetimibe may  lead to an excess of
triglycerides and secondary inhibition of fatty acid absorption and
triglyceride synthesis. Moreover, a clinical study has revealed that
ezetimibe is effective for improvement in non-alcoholic fatty liver
disease (NAFLD). Yoneda et al. [18] conducted a study in 10 NAFLD
patients receiving ezetimibe (10 mg/day) for 6 months, and carried
out liver biopsy for histopathological examination before and after
treatment. They reported that the ezetimibe treatment signiﬁcantly
decreased the amount of fat droplets in the liver. Furthermore, a
study employing magnetic resonance imaging showed that eze-
timibe combined with dietary therapy signiﬁcantly reduced the
hepatic fat area compared with dietary therapy alone [19]. Fatty
liver is closely associated with insulin sensitivity. Therefore, it is
expected that a decrease in lipid accumulation in the liver due
to ezetimibe treatment would have a favorable impact on hepatic
insulin sensitivity. That is, the improvement in postprandial glucose
metabolism is suggested to be secondary to improvement in fatty
acid metabolism and reduced hepatic lipid accumulation resulting
from inhibition of chylomicron secretion by ezetimibe.
In our present study, glucose and insulin levels at 30 min
and 60 min  after meal were not measured because multiple
blood sampling is invasive for our study subjects (healthy volun-
teers) excluding patients with diabetes. Although our preliminary
data suggested a possible involvement of ezetimibe in glucose
metabolism, measurements of glucose and insulin levels at 30 min
and 60 min after a meal are required to conﬁrm this correlation.
The prevalence of dyslipidemia is increasing in modern Japan
because of westernization of the diet and ezetimibe is a reasonable
etiologic therapy for dyslipidemia. Since this drug also improves
postprandial metabolism, ezetimibe could be a beneﬁcial treat-
ment option for patients who  have dyslipidemia accompanied by
obesity or metabolic syndrome. The present study had no control
group and a limited sample size, as well as investigating rela-
tively few laboratory parameters. It is difﬁcult to establish that
ezetimibe treatment itself improved postprandial lipid and glu-
cose metabolism. A randomized controlled trial should therefore
be conducted in the future.References
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